https://www.selleckchem.com/pr....oducts/sitravatinib-
However, the often necessary off-label use can cause difficulties in everyday clinical practice. The attending physician should therefore always be informed if aplanned therapy involves off-label use. Previously approved alternatives should be considered and patients should be adequately informed. It can be stated that the enormous developments over the last few years and the increasingly good evidence offer in many cases very promising systemic treatment concepts despite the frequent lack of clinical studies in the field o
Like
Comment
Share
